nih-gov/www.ncbi.nlm.nih.gov/books/n/mlprobe/ml083/index.html?report=reader
2025-03-17 02:05:34 +00:00

551 lines
160 KiB
Text

<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
<head>
<!-- For pinger, set start time and add meta elements. -->
<script type="text/javascript">var ncbi_startTime = new Date();</script>
<!-- Logger begin -->
<meta name="ncbi_db" content="books">
<meta name="ncbi_pdid" content="book-part">
<meta name="ncbi_acc" content="NBK47338">
<meta name="ncbi_domain" content="mlprobe">
<meta name="ncbi_report" content="reader">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_objectid" content="">
<meta name="ncbi_pcid" content="/NBK47338/?report=reader">
<meta name="ncbi_pagename" content="Identification of activators for the M2 isoform of human pyruvate kinase - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf">
<meta name="ncbi_bookparttype" content="chapter">
<meta name="ncbi_app" content="bookshelf">
<!-- Logger end -->
<!--component id="Page" label="meta"/-->
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Identification of activators for the M2 isoform of human pyruvate kinase - Probe Reports from the NIH Molecular Libraries Program - NCBI Bookshelf</title>
<meta charset="utf-8">
<meta name="apple-mobile-web-app-capable" content="no">
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
<meta name="jr-col-layout" content="auto">
<meta name="jr-prev-unit" content="/books/n/mlprobe/ml084/?report=reader">
<meta name="jr-next-unit" content="/books/n/mlprobe/ml081/?report=reader">
<meta name="bk-toc-url" content="/books/n/mlprobe/?report=toc">
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
<meta name="citation_inbook_title" content="Probe Reports from the NIH Molecular Libraries Program [Internet]">
<meta name="citation_title" content="Identification of activators for the M2 isoform of human pyruvate kinase">
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
<meta name="citation_date" content="2010/08/06">
<meta name="citation_author" content="Douglas Auld">
<meta name="citation_author" content="Min Shen">
<meta name="citation_author" content="Amanda P Skoumbourdis">
<meta name="citation_author" content="Jian-kang Jiang">
<meta name="citation_author" content="Matthew Boxer">
<meta name="citation_author" content="Noel Southall">
<meta name="citation_author" content="James Inglese">
<meta name="citation_author" content="Craig Thomas">
<meta name="citation_pmid" content="21433354">
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK47338/">
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
<meta name="DC.Title" content="Identification of activators for the M2 isoform of human pyruvate kinase">
<meta name="DC.Type" content="Text">
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
<meta name="DC.Contributor" content="Douglas Auld">
<meta name="DC.Contributor" content="Min Shen">
<meta name="DC.Contributor" content="Amanda P Skoumbourdis">
<meta name="DC.Contributor" content="Jian-kang Jiang">
<meta name="DC.Contributor" content="Matthew Boxer">
<meta name="DC.Contributor" content="Noel Southall">
<meta name="DC.Contributor" content="James Inglese">
<meta name="DC.Contributor" content="Craig Thomas">
<meta name="DC.Date" content="2010/08/06">
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK47338/">
<meta name="description" content="The expression of human pyruvate kinase M2 (hPK-M2) in cancer cells appears to be critical for tumor cell growth and proliferation in vivo. Because the PK-M2 isoform is expressed in all cancer cells studied, it represents a target for drug development that could potentially enable tumor cells to return to a normal state of metabolism. If this novel strategy for targeting malignancy were successful, it would be applicable to diverse types of cancer. The probes ML083 (CID-650361) and ML082 (CID-654376) are members of a series of highly specific allosteric activators for the tumor-specific isoform of human pyruvate kinase (M2 isoform). Both probes affect the cooperativity of phosphoenolpyruvate (PEP) binding with little effect on adenosine diphosphate (ADP) binding in a manner similar to FBP.">
<meta name="og:title" content="Identification of activators for the M2 isoform of human pyruvate kinase">
<meta name="og:type" content="book">
<meta name="og:description" content="The expression of human pyruvate kinase M2 (hPK-M2) in cancer cells appears to be critical for tumor cell growth and proliferation in vivo. Because the PK-M2 isoform is expressed in all cancer cells studied, it represents a target for drug development that could potentially enable tumor cells to return to a normal state of metabolism. If this novel strategy for targeting malignancy were successful, it would be applicable to diverse types of cancer. The probes ML083 (CID-650361) and ML082 (CID-654376) are members of a series of highly specific allosteric activators for the tumor-specific isoform of human pyruvate kinase (M2 isoform). Both probes affect the cooperativity of phosphoenolpyruvate (PEP) binding with little effect on adenosine diphosphate (ADP) binding in a manner similar to FBP.">
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK47338/">
<meta name="og:site_name" content="NCBI Bookshelf">
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-mlprobe-lrg.png">
<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@ncbibooks">
<meta name="bk-non-canon-loc" content="/books/n/mlprobe/ml083/?report=reader">
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK47338/">
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&amp;subset=latin" rel="stylesheet" type="text/css">
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
<meta name="format-detection" content="telephone=no">
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
<meta name="ncbi_phid" content="CE8D1AE77D669D310000000000260021.m_5">
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
<body>
<!-- Book content! -->
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK47338/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
<style type="text/css">.st0{fill:#939598;}</style>
<g>
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
</g>
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/mlprobe/ml084/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Identification of activators for the M2 isoform of human pyruvate kinase</div><div class="j">Probe Reports from the NIH Molecular Libraries Program [Internet]</div></div><div class="tail"><a href="/books/n/mlprobe/ml081/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK47338/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK47338/&amp;text=Identification%20of%20activators%20for%20the%20M2%20isoform%20of%20human%20pyruvate%20kinase"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/mlprobe/?report=reader">Title Information</a><a href="/books/n/mlprobe/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK47338/?report=classic">Switch to classic view</a><a href="/books/NBK47338/pdf/Bookshelf_NBK47338.pdf">PDF (555K)</a><a href="/books/NBK47338/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK47338%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D1AE77D669D310000000000260021.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">&#10008;</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">&#10008;</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">&#9664;</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">&#9654;</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK47338_"><span class="title" itemprop="name">Identification of activators for the M2 isoform of human pyruvate kinase</span></h1><p class="contribs">Auld D, Shen M, Skoumbourdis AP, et al.</p><p class="fm-aai"><a href="#_NBK47338_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p> The expression of human pyruvate kinase M2 (hPK-M2) in cancer cells appears to be critical for tumor cell growth and proliferation in vivo. Because the PK-M2 isoform is expressed in all cancer cells studied, it represents a target for drug development that could potentially enable tumor cells to return to a normal state of metabolism. If this novel strategy for targeting malignancy were successful, it would be applicable to diverse types of cancer. The probes ML083 (CID-650361) and ML082 (CID-654376) are members of a series of highly specific allosteric activators for the tumor-specific isoform of human pyruvate kinase (M2 isoform). Both probes affect the cooperativity of phosphoenolpyruvate (PEP) binding with little effect on adenosine diphosphate (ADP) binding in a manner similar to FBP.</p></div><div class="h2"></div><p>
<b>Assigned Assay Grant #:</b> 1 R03 MH085679-01 </p><p>
<b>Screening Center Name &#x00026; PI:</b> NIH Chemical Genomics Center,
Christopher Austin </p><p>
<b>Chemistry Center Name &#x00026; PI:</b> NIH Chemical Genomics Center,
Christopher Austin </p><p>
<b>Assay Submitter &#x00026; Institution:</b> Dr. Matthew George Vander Heiden,
Harvard </p><p><b>PubChem Primary Bioassay Identifier (AID):</b>
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1631" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1631</a></p><div id="ml083.probestruct"><h2 id="_ml083_probestruct_">Probe Structure and Characteristics</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml083tu1"><a href="/books/NBK47338/table/ml083.tu1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figml083tu1" rid-ob="figobml083tu1"><img class="small-thumb" src="/books/NBK47338/table/ml083.tu1/?report=thumb" src-large="/books/NBK47338/table/ml083.tu1/?report=previmg" alt="Probe 1 Structure &#x00026; Characteristics." /></a><div class="icnblk_cntnt"><h4 id="ml083.tu1"><a href="/books/NBK47338/table/ml083.tu1/?report=objectonly" target="object" rid-ob="figobml083tu1">Table</a></h4><p class="float-caption no_bottom_margin">Probe 1 Structure &#x00026; Characteristics. </p></div></div><div id="ml083.fu1" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu1.jpg" alt="Image ml083fu1" /></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml083tu2"><a href="/books/NBK47338/table/ml083.tu2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figml083tu2" rid-ob="figobml083tu2"><img class="small-thumb" src="/books/NBK47338/table/ml083.tu2/?report=thumb" src-large="/books/NBK47338/table/ml083.tu2/?report=previmg" alt="PubChem Primary Bioassay Identifier (AID): 1631." /></a><div class="icnblk_cntnt"><h4 id="ml083.tu2"><a href="/books/NBK47338/table/ml083.tu2/?report=objectonly" target="object" rid-ob="figobml083tu2">Table</a></h4><p class="float-caption no_bottom_margin">PubChem Primary Bioassay Identifier (AID): 1631. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml083tu3"><a href="/books/NBK47338/table/ml083.tu3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figml083tu3" rid-ob="figobml083tu3"><img class="small-thumb" src="/books/NBK47338/table/ml083.tu3/?report=thumb" src-large="/books/NBK47338/table/ml083.tu3/?report=previmg" alt="Probe 2 Structure &#x00026; Characteristics." /></a><div class="icnblk_cntnt"><h4 id="ml083.tu3"><a href="/books/NBK47338/table/ml083.tu3/?report=objectonly" target="object" rid-ob="figobml083tu3">Table</a></h4><p class="float-caption no_bottom_margin">Probe 2 Structure &#x00026; Characteristics. </p></div></div><div id="ml083.fu2" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu2.jpg" alt="Image ml083fu2" /></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml083tu4"><a href="/books/NBK47338/table/ml083.tu4/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figml083tu4" rid-ob="figobml083tu4"><img class="small-thumb" src="/books/NBK47338/table/ml083.tu4/?report=thumb" src-large="/books/NBK47338/table/ml083.tu4/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ml083.tu4"><a href="/books/NBK47338/table/ml083.tu4/?report=objectonly" target="object" rid-ob="figobml083tu4">Table</a></h4></div></div></div><div id="ml083.rationale"><h2 id="_ml083_rationale_">Recommendations for the scientific use of these probes</h2><div id="ml083.s5"><h3>Specific Aim</h3><p>We aimed to discover and optimize selective modulators of human pyruvate kinase
M2 (hPK-M2), a splice isoform of pyruvate kinase that is specifically expressed
in tumor cells. The research has the following specific aims: (1) To identify both activators and
inhibitors of human M2 PK using a quantitative high-throughput screening
approach against the MLSMR, containing 300,000 small molecules. (2) To confirm the potency of these
compounds in a panel of secondary assays, including selectivity assays for the
human R/L and M1 isoforms of pyruvate kinase which are expressed in most
differentiated tissues.</p></div><div id="ml083.s6"><h3>Significance</h3><p>Expression of hPK-M2 in cancer cells appears critical for tumor cell growth and
proliferation <i>in vivo</i>. In addition, the ability of PK-M2 to be
regulated by both FBP and tyrosine phosphorylated proteins is necessary for
cancer cell proliferation. Because PK-M2 is the sole pyruvate kinase isoform
expressed in all cancer cells studied, it represents a target for drug
development that would enable the inhibition of glucose metabolism in a
relatively tumor-specific manner. If this novel strategy for targeting
malignancy were successful, it would be applicable to diverse types of
cancer.</p></div><div id="ml083.s7"><h3>Rationale</h3><p>PK is a tetrameric enzyme composed of four identical monomers that form a dimer
of dimers in the final tetrameric structure. In humans, the M2, L, and R
isozymes are activated by fructose-1,6-bis phosphate (FBP) that binds to a
flexible loop region at the interface of the two dimers. Activation of PK shifts
the enzyme to a state showing high affinity for PEP and relieves the cooperative
kinetics of PEP binding found in the unactivated form (<a class="bibr" href="#ml083.r1" rid="ml083.r1">1</a>). In contrast, the M1 isoform is not regulated by
FBP and displays only high affinity PEP binding similar to the activated state
of PK. Importantly, the differentially spliced exons that distinguish PK-M1 from
PK-M2 are identical in size and encode a 56 amino acid stretch that covers the
activation loop that allows PK-M2, but not PK-M1, to be allosterically activated
by FBP (<a class="bibr" href="#ml083.r3" rid="ml083.r3">3</a>).</p><p>Tumor cells undergo a metabolic transformation that is required to supply the
biochemical precursors necessary for rapid cell growth and proliferation. Otto
Warburg was first to demonstrate in the 1920s that tumor cells show aberrant
energy metabolism and noted that cancer cells produce lactate even under aerobic
conditions (<a class="bibr" href="#ml083.r2" rid="ml083.r2 ml083.r3 ml083.r4">2&#x02013;4</a>). The property of aerobic glycolysis in tumor cells
has been termed the &#x0201c;Warburg effect.&#x0201d; This work has
spawned generations of research on tumor metabolism and the high rate of glucose
used by tumors is exploited clinically today through the identification of tumor
cells using 18-fluorodeoxyglucose-PET scanning. This metabolic transformation of
tumor cells can be achieved by altering the expression of metabolic enzymes.
Current evidence suggests that expression of PK-M2 in tumor cells has a large
influence on this process, and that this is due to the unique allosteric
regulation of PK-M2 (<a class="bibr" href="#ml083.r2" rid="ml083.r2">2</a>,<a class="bibr" href="#ml083.r3" rid="ml083.r3">3</a>). In a recent study it was shown
that knock-down of PK-M2 and expression of PK-M1 in tumor cell lines was
sufficient to relieve the Warburg effect and rescue normal cellular respiration
(<a class="bibr" href="#ml083.r2" rid="ml083.r2">2</a>). In this study, tumor cells
engineered to express PK-M1 showed a reduced ability to form tumors in nude
mouse xenografts. As well, in related study, a link between PK-M2 and growth
factors that produce phosphotyrosine polypeptides in tumor cells was
demonstrated (<a class="bibr" href="#ml083.r3" rid="ml083.r3">3</a>). In that study it
was found that various phosphotyrosine peptides can bind to PK-M2 near the
activation loop, which results in the removal of FBP from the enzyme which
effectively down-regulates PK-M2 activity. This cascade leads to a building up
of glycolytic intermediates that can be diverted towards nucleotide and lipid
biosynthesis required for cell growth and proliferation.<sup>3</sup> These
studies suggest that growth factor signaling decreases PK-M2 activity, and that
this decrease in activity contributes to both the Warburg effect (<a class="bibr" href="#ml083.r4" rid="ml083.r4">4</a>) and the ability of tumor cells to
proliferate. Taken together, these studies imply a therapeutic strategy where
activation of PK-M2 should return normal cellular metabolism in a manner similar
to the experiments described above where tumor cells were rescued by the
expression of the constitutively active PK-M1 isozyme.</p><div id="ml083.fu3" class="figure bk_fig"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu3.jpg" alt="A) Shown is normal respiration occurring in non-cancerous cell-types" /></div><div class="caption"><p><b>A)</b> Shown is normal respiration occurring in non-cancerous
cell-types. PK-M1 is constitutively active and acts primarily to drive
ATP formation. <b>B)</b> Shown is altered metabolism that occurs
in cancer cells. In this case, the activity of the PK-M2 isoform is
activated by phosphorylated sugars (e.g. FBP) and inhibited by
tyrosine-phosphorylated proteins derived from growth factor signaling.
The decrease in activity of PK-M2 in response to growth signals is
predicted to build-up intermediates of glycolysis and feed proliferation
of the cancer cells.</p></div></div></div></div><div id="ml083.s8"><h2 id="_ml083_s8_">Assay Implementation and Screening</h2><div id="ml083.s9"><h3>PubChem Bioassay Name</h3><p><i>Dmel</i> lipid storage</p></div><div id="ml083.s10"><h3>List of PubChem bioassay identifiers generated for this screening project
(AIDS)</h3><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml083tu5"><a href="/books/NBK47338/table/ml083.tu5/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figml083tu5" rid-ob="figobml083tu5"><img class="small-thumb" src="/books/NBK47338/table/ml083.tu5/?report=thumb" src-large="/books/NBK47338/table/ml083.tu5/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ml083.tu5"><a href="/books/NBK47338/table/ml083.tu5/?report=objectonly" target="object" rid-ob="figobml083tu5">Table</a></h4></div></div></div><div id="ml083.s11"><h3>Primary Assay Description as defined in PubChem</h3><div id="ml083.s12"><h4>Overview</h4><p>To develop a robust assay for PK we took advantage of a well-utilized
luminescent assay detection system for protein kinases (<a class="bibr" href="#ml083.r5" rid="ml083.r5">5</a>,<a class="bibr" href="#ml083.r6" rid="ml083.r6">6</a>).
Typically, these assays use the ATP-dependent reaction catalyzed by firefly
luciferase to measure ATP depletion by protein kinases. In the present assay
we applied this assay to measure ATP production catalyzed by PK. This
provides for a robust increase in luminescent signal upon ATP product
formation (<a class="figpopup" href="/books/NBK47338/figure/ml083.f1/?report=objectonly" target="object" rid-figpopup="figml083f1" rid-ob="figobml083f1">Figure 2</a>) (<a class="bibr" href="#ml083.r7" rid="ml083.r7">7</a>). The primary high-throughput
screen was performed in 1536-well microtiter plates using 4 uL/well assay
volume with final concentrations of 0.1 nM human PK M2, 0.5 mM PEP, 0.1 mM
ADP in assay buffer that contained 50 mM Imidazole pH 7.2, 50 mM KCl, 7 mM
MgCl2, 0.01% Tween, 0.05% BSA. For compound transfer
we used a pintool equipped with a 1536 pins that each transferred 23 nL of a
DMSO solution containing compound. The enzymatic reaction was allowed to
proceed for 60 minutes and then ATP was detected using a bioluminescent
detection reagent containing D-luciferin and firefly luciferase (Kinase-Glo,
Promega) (<a class="bibr" href="#ml083.r8" rid="ml083.r8">8</a>). The detection
reagent also effectively stopped the PK reaction. Luminescence was then
measured on the Perkin Elmer Viewlux using an exposure of 2 secs (with 2X
binning). The final concentration of DMSO in the enzyme assay is
0.5% and was found not to affect the assay signal.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml083f1" co-legend-rid="figlgndml083f1"><a href="/books/NBK47338/figure/ml083.f1/?report=objectonly" target="object" title="Figure 2" class="img_link icnblk_img figpopup" rid-figpopup="figml083f1" rid-ob="figobml083f1"><img class="small-thumb" src="/books/NBK47338/bin/ml083f1.gif" src-large="/books/NBK47338/bin/ml083f1.jpg" alt="Figure 2. Pyruvate kinase-luciferase coupled assay." /></a><div class="icnblk_cntnt" id="figlgndml083f1"><h4 id="ml083.f1"><a href="/books/NBK47338/figure/ml083.f1/?report=objectonly" target="object" rid-ob="figobml083f1">Figure 2</a></h4><p class="float-caption no_bottom_margin">Pyruvate kinase-luciferase coupled assay. </p></div></div><p>All compounds were screened using a qHTS approach, where compounds are
assayed using at least seven concentrations to generate
concentration-response curves for every compounds (<a class="bibr" href="#ml083.r7" rid="ml083.r7">7</a>). The methodology for creating a
concentration-titration series between successive copies of library plates
for the purpose of large-scale titration-based screening has been described
(<a class="bibr" href="#ml083.r9" rid="ml083.r9">9</a>). Briefly, qHTS uses an
inter-plate dilution method where the first plate contains the highest
concentration of a set of compounds in DMSO, while subsequent plates contain
the same compounds in the same well locations, but at successive lower
concentrations. Using the protocol outlined above we calculated a plate
throughput of 18 plates/hr or approximately 7 samples/sec on the Kalypsys
robotic system which means that a 7 point CRC was obtained every second on
the robotic system.</p></div></div><div id="ml083.s13"><h3>Summary of the Primary Screen</h3><div id="ml083.s14"><h4>Assay protocol</h4><p>The optimized 1536-well protocol is given in <a class="figpopup" href="/books/NBK47338/table/ml083.t1/?report=objectonly" target="object" rid-figpopup="figml083t1" rid-ob="figobml083t1">Table 1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml083t1"><a href="/books/NBK47338/table/ml083.t1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figml083t1" rid-ob="figobml083t1"><img class="small-thumb" src="/books/NBK47338/table/ml083.t1/?report=thumb" src-large="/books/NBK47338/table/ml083.t1/?report=previmg" alt="Table 1. Final 1536-well assay protocol." /></a><div class="icnblk_cntnt"><h4 id="ml083.t1"><a href="/books/NBK47338/table/ml083.t1/?report=objectonly" target="object" rid-ob="figobml083t1">Table 1</a></h4><p class="float-caption no_bottom_margin">Final 1536-well assay protocol. </p></div></div><div id="ml083.f2" class="figure bk_fig"><div class="graphic"><img src="/books/NBK47338/bin/ml083f2.jpg" alt="Figure 2. qHTS Performance Summary." /></div><h3><span class="label">Figure 2</span><span class="title">qHTS Performance Summary</span></h3></div><div id="ml083.s15"><h5>Identification of hPK M2 Activators</h5><p>Following the qHTS the CRC data was subjected to a classification scheme
to rank the quality of the CRCs as described by Inglese and coworkers
(<a class="bibr" href="#ml083.r7" rid="ml083.r7">7</a>) (see <a class="figpopup" href="/books/NBK47338/figure/ml083.f3/?report=objectonly" target="object" rid-figpopup="figml083f3" rid-ob="figobml083f3">scheme 1</a>). Briefly, CRCs are
placed into four classes. Class 1 contains complete CRCs showing both
upper and lower asymptotes and r<sup>2</sup> values &#x0003e; 0.9. Class
2 contains incomplete CRCs lacking the lower asymptote and shows
r<sup>2</sup> values greater than 0.9. Class 3 curves are of the
lowest confidence because they are defined by a single concentration
point where the minimal acceptable activity is set at 3 SD of the mean
activity calculated from the lowest tested concentration. Finally, class
4 contains compounds that do not show any CRCs and are therefore
classified as inactive.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml083f3" co-legend-rid="figlgndml083f3"><a href="/books/NBK47338/figure/ml083.f3/?report=objectonly" target="object" title="Scheme 1" class="img_link icnblk_img figpopup" rid-figpopup="figml083f3" rid-ob="figobml083f3"><img class="small-thumb" src="/books/NBK47338/bin/ml083f3.gif" src-large="/books/NBK47338/bin/ml083f3.jpg" alt="Scheme 1. Example qHTS data and classification scheme for assignment of resulting curve-fit data into classes." /></a><div class="icnblk_cntnt" id="figlgndml083f3"><h4 id="ml083.f3"><a href="/books/NBK47338/figure/ml083.f3/?report=objectonly" target="object" rid-ob="figobml083f3">Scheme 1</a></h4><p class="float-caption no_bottom_margin">Example qHTS data and classification scheme for assignment of
resulting curve-fit data into classes. <i>Top</i>, qHTS curve-fit data from AID-361 binned into
curve classifications 1&#x02013;4 based classification
criteria. <i>Below</i>, Examples of curves fitting the
following <a href="/books/NBK47338/figure/ml083.f3/?report=objectonly" target="object" rid-ob="figobml083f3">(more...)</a></p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml083f4" co-legend-rid="figlgndml083f4"><a href="/books/NBK47338/figure/ml083.f4/?report=objectonly" target="object" title="Figure 3" class="img_link icnblk_img figpopup" rid-figpopup="figml083f4" rid-ob="figobml083f4"><img class="small-thumb" src="/books/NBK47338/bin/ml083f4.gif" src-large="/books/NBK47338/bin/ml083f4.jpg" alt="Figure 3. Summary of activity from the qHTS." /></a><div class="icnblk_cntnt" id="figlgndml083f4"><h4 id="ml083.f4"><a href="/books/NBK47338/figure/ml083.f4/?report=objectonly" target="object" rid-ob="figobml083f4">Figure 3</a></h4><p class="float-caption no_bottom_margin">Summary of activity from the qHTS. The table summarizes the number actives associated with CRC
classes described in Scheme
1(highlighted in red are the percentages for the high
quality activating CRCs. The flow chart below summarizes the how
this information <a href="/books/NBK47338/figure/ml083.f4/?report=objectonly" target="object" rid-ob="figobml083f4">(more...)</a></p></div></div></div></div></div><div id="ml083.s16"><h3>Probe Characterization</h3><div id="ml083.fu4" class="figure bk_fig"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu4.jpg" alt="Mode of action." /></div><h3><span class="title">Mode of action</span></h3><div class="caption"><p>Both CID-650361 (<b>A</b>) and CID-654376 (<b>B</b>) affect
the cooperativity of PEP binding with little affect on ADP binding in a
manner similar to FBP but with lower efficacy. Kinetics of substrate
binding in the presence (open circles) or absence (filled squares) of
activator (10 &#x003bc;M was used). Vo, initial rate in pmol/min as
determined in the PK-LDH coupled assay</p></div></div><div id="ml083.s18"><h4>Synthesis of analogs CID-650361</h4><div id="ml083.s19"><h5>General procedure for the synthesis of analogues</h5><p>The bis-sulfonamide was elaborated upon via the synthetic strategy
outline in <a class="figpopup" href="/books/NBK47338/figure/ml083.f5/?report=objectonly" target="object" rid-figpopup="figml083f5" rid-ob="figobml083f5">Scheme 1</a>. A Boc
protected piperizine (alternate ring systems were additionally explored;
for instance, 1,4-diazepane,
2,6-diazabicyclo[3.2.1]octane,
2,5-diazabicyclo[2.2.1]heptane,
2-methylpiperazine and piperazin-2-one) was treated with selected
sulfonyl chlorides in basic methylene chloride. Boc removal was
accomplished by treatment with trifluoroacetic acid, and a subsequent
treatment with selected sulfonyl chlorides in basic methylene chloride
provided numerous analogues.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml083f5" co-legend-rid="figlgndml083f5"><a href="/books/NBK47338/figure/ml083.f5/?report=objectonly" target="object" title="Scheme 1" class="img_link icnblk_img figpopup" rid-figpopup="figml083f5" rid-ob="figobml083f5"><img class="small-thumb" src="/books/NBK47338/bin/ml083f5.gif" src-large="/books/NBK47338/bin/ml083f5.jpg" alt="Scheme 1" /></a><div class="icnblk_cntnt" id="figlgndml083f5"><h4 id="ml083.f5"><a href="/books/NBK47338/figure/ml083.f5/?report=objectonly" target="object" rid-ob="figobml083f5">Scheme 1</a></h4></div></div><p>Additionally, numerous derivatives were synthesized that incorporated
selected amide functions in place of sulfonamides. The synthesis of
these analogues followed similar methods and is outlined in <a class="figpopup" href="/books/NBK47338/figure/ml083.f6/?report=objectonly" target="object" rid-figpopup="figml083f6" rid-ob="figobml083f6">Scheme 2</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml083f6" co-legend-rid="figlgndml083f6"><a href="/books/NBK47338/figure/ml083.f6/?report=objectonly" target="object" title="Scheme 2" class="img_link icnblk_img figpopup" rid-figpopup="figml083f6" rid-ob="figobml083f6"><img class="small-thumb" src="/books/NBK47338/bin/ml083f6.gif" src-large="/books/NBK47338/bin/ml083f6.jpg" alt="Scheme 2" /></a><div class="icnblk_cntnt" id="figlgndml083f6"><h4 id="ml083.f6"><a href="/books/NBK47338/figure/ml083.f6/?report=objectonly" target="object" rid-ob="figobml083f6">Scheme 2</a></h4></div></div><p>It was also of interest to explore selected sulfone moieties in place of
the sulfonamides. To achieve these derivatives, we first displaced the
halogen on 4-bromopiperidine (alternate ring systems were additionally
explored; for instance 4-bromoazepane) via attach by selected aromatic
thiols in basic <i>N,N</i>-dimethylformamide (<a class="figpopup" href="/books/NBK47338/figure/ml083.f7/?report=objectonly" target="object" rid-figpopup="figml083f7" rid-ob="figobml083f7">Scheme 3</a>). Oxidation with
meta-chloroperbenzoic acid provided the sulfones and the remainder of
the synthesis followed the strategy outline in <a class="figpopup" href="/books/NBK47338/figure/ml083.f5/?report=objectonly" target="object" rid-figpopup="figml083f5" rid-ob="figobml083f5">Scheme 1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml083f7" co-legend-rid="figlgndml083f7"><a href="/books/NBK47338/figure/ml083.f7/?report=objectonly" target="object" title="Scheme 3" class="img_link icnblk_img figpopup" rid-figpopup="figml083f7" rid-ob="figobml083f7"><img class="small-thumb" src="/books/NBK47338/bin/ml083f7.gif" src-large="/books/NBK47338/bin/ml083f7.jpg" alt="Scheme 3" /></a><div class="icnblk_cntnt" id="figlgndml083f7"><h4 id="ml083.f7"><a href="/books/NBK47338/figure/ml083.f7/?report=objectonly" target="object" rid-ob="figobml083f7">Scheme 3</a></h4></div></div><p>Additional efforts surrounded the incorporation of selected functionality
directly on the piperizine ring system (alternate ring systems were
additionally explored; for instance, 1,4-diazepane, 2-methylpiperazine
and piperazin-2-one). In these efforts, the utility of appropriately
substituted piperazin-2-ones were treated with lithium
hexamethyldisilazide followed by Selectfluor&#x000ae; to accomplish
the fluorination of the ring system. These analogues were explored
further by direct reduction of the carbonyl with borane (<a class="figpopup" href="/books/NBK47338/figure/ml083.f8/?report=objectonly" target="object" rid-figpopup="figml083f8" rid-ob="figobml083f8">Scheme 4</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml083f8" co-legend-rid="figlgndml083f8"><a href="/books/NBK47338/figure/ml083.f8/?report=objectonly" target="object" title="Scheme 4" class="img_link icnblk_img figpopup" rid-figpopup="figml083f8" rid-ob="figobml083f8"><img class="small-thumb" src="/books/NBK47338/bin/ml083f8.gif" src-large="/books/NBK47338/bin/ml083f8.jpg" alt="Scheme 4" /></a><div class="icnblk_cntnt" id="figlgndml083f8"><h4 id="ml083.f8"><a href="/books/NBK47338/figure/ml083.f8/?report=objectonly" target="object" rid-ob="figobml083f8">Scheme 4</a></h4></div></div></div><div id="ml083.s20"><h5>SAR of CID650361 analogs</h5><p>The SAR of the bis-sulfonamide chemotype was explored on multiple
fronts. The central ring system was found to be necessary as was the
presence of the sulfonamides (amides were not active). Further, both
aryl derivatives were altered to gain an appreciation of their
effect on activity. The lone phenyl ring was explored with standard
substitutions (F, Me, OMe, Cl, CF3) at all positions (ortho, meta,
para) and several di-substitutions were explored (see table).
Additionally, the
2,3-dihydrobenzo[b][1,4]dioxine
heterocycle was altered. Related heterocycles and substituted phenyl
rings were explored. Symmetric versions of this chemotype were also
explored and found to be active.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml083tu6"><a href="/books/NBK47338/table/ml083.tu6/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figml083tu6" rid-ob="figobml083tu6"><img class="small-thumb" src="/books/NBK47338/table/ml083.tu6/?report=thumb" src-large="/books/NBK47338/table/ml083.tu6/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ml083.tu6"><a href="/books/NBK47338/table/ml083.tu6/?report=objectonly" target="object" rid-ob="figobml083tu6">Table</a></h4></div></div></div></div><div id="ml083.s21"><h4>Synthesis of analogs CID-654376</h4><p>The 2-(benzyl)pyridazin-3(2H)-one based heterocycle was expanded via the
synthetic strategy outline in <a class="figpopup" href="/books/NBK47338/figure/ml083.f9/?report=objectonly" target="object" rid-figpopup="figml083f9" rid-ob="figobml083f9">Scheme
5</a>. Mixing a 5-substituted thiophene-2-carbaldehyde (substitutions
included alkyl groups and halogens) and ethyl 2-azidoacetate in basic
ethanol provided the (Z)-ethyl
2-azido-3-(5-substituted-thiophen-2-yl)acrylates, which can be directly
cyclized to ethyl
2-substituted-4H-thieno[3,2-b]pyrrole-5-carboxylates
by refluxing in O-xylene. Treatment of this heterocycle with piperidine and
formaldehyde in glacial acetic acid produced the ethyl
2-methyl-6-(piperidin-1-ylmethyl)-4H-thieno[3,2-b]pyrrole-5-carboxylates
that can be methylated (the quarternary amine is preferred) and converted to
the aldehyde. Treatment of the ethyl
6-formyl-2-substituted-4H-thieno[3,2-b]pyrrole-5-carboxylates
with methyl iodide in basic conditions (K<sub>2</sub>CO<sub>3</sub>, DMF)
directly methylates the pyrole nitrogen [NOTE: it is essential
to alkylate the pyrole nitrogen at this synthetic step to avoid competition
with the pyridazin-3(2H)-one nitrogens]. Treatment with
hydrazine forms the pyridazin-3(2H)-one ring system and alkylation with
selected benzyl bromides provides the final structures.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figml083f9" co-legend-rid="figlgndml083f9"><a href="/books/NBK47338/figure/ml083.f9/?report=objectonly" target="object" title="Scheme 5" class="img_link icnblk_img figpopup" rid-figpopup="figml083f9" rid-ob="figobml083f9"><img class="small-thumb" src="/books/NBK47338/bin/ml083f9.gif" src-large="/books/NBK47338/bin/ml083f9.jpg" alt="Scheme 5" /></a><div class="icnblk_cntnt" id="figlgndml083f9"><h4 id="ml083.f9"><a href="/books/NBK47338/figure/ml083.f9/?report=objectonly" target="object" rid-ob="figobml083f9">Scheme 5</a></h4></div></div><div id="ml083.s22"><h5>General procedure for the synthesis of analogues</h5><div id="ml083.fu5" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu6.jpg" alt="Image ml083fu6" /></div></div><p>Synthesis of (Z)-ethyl 2-azido-3-(5-substituted-thiophen-2-yl)acrylates.
A solution of sodium (2.76 g, 120 mmol) in absolute EtOH (120 ml) was
cooled in an ice-bath and a mixture of 5-substituted-2-formylthiophene
(5.73 g, 30 mmol) and ethyl azidoacetate (15.49 g, 120 mmol) was added
dropwise during 30 min period. The bath was removed and the reaction
mixture was stirred at room temperature for another 30 min. A cold
solution of saturated aqueous NH<sub>4</sub>Cl solution (100 ml) was
added and the resulting solution was extracted with diethyl ether (3x100
ml) and the combined organic layers were washed with brine (200 ml),
dried over Na<sub>2</sub>SO<sub>4</sub>. After removing diethyl ether
under reduced pressure, the crude product was purified by column
chromatography (EtOAc/Hexane 1/50) to give substituted acrylates as
light yellow solids</p><div id="ml083.fu6" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu7.jpg" alt="Image ml083fu7" /></div></div><p>Synthesis of ethyl
2-substituted-4H-thieno[3,2-b]pyrrole-5-carboxylate.</p><p>A solution of substituted acrylates (3.81 g, 12.6 mmol) in
<i>o</i>-xylene was refluxed for 20 min. After removing
the <i>o</i>-xylene, the crude product was purified by column
chromatography (EtOAc/Hexane 1/10) to give substituted
thieno[3,2-<i>b</i>]pyrroles as
white solids.</p><div id="ml083.fu7" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu8.jpg" alt="Image ml083fu8" /></div></div><p>Synthesis of ethyl
2-substituted-6-(piperidin-1-ylmethyl)-4H-thieno[3,2-b]pyrrole-5-carboxylate.</p><p>Piperidine (1.02 ml, 10.2 mmol), 37% aqueous formaldehyde
(0.80 ml, 10.2 mmol) and substituted
thieno[3,2-<i>b</i>]pyrrole (2.80
g, 10.2 mmol) were added to glacial acetic acid (3 ml) with ice-bath
cooling. The mixture was heated to 95 &#x000b0;C for 30 min and
allowed to react at room temperature overnight. After adding
H<sub>2</sub>O (10 ml), the mixture was adjusted to pH 8 by slow
addition of saturated aqueous K<sub>2</sub>CO<sub>3</sub> solution and
resulting solution was extracted with diethyl ether (3x15 ml). The
combined organic layers were washed with brine, dried over
Na<sub>2</sub>SO<sub>4</sub>. After removing the organic solvent
under reduced pressure, the residue was purified by column
chromatography (EtOAc/Hexane 1/2) to give the desired substituted
Mannich bases as white solids</p><div id="ml083.fu8" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu9.jpg" alt="Image ml083fu9" /></div></div><p>Synthesis of
1-((5-(ethoxycarbonyl)-2-substituted-4H-thieno[3,2-b]pyrrol-6-yl)methyl)-1-methylpiperidinium
iodides.</p><p>A solution of substituted Mannich bases (2.70 g, 7.30 mmol) in diethyl
ether (60 ml) was added dropwise to iodomethane (15 ml) with stirring in
30 min. The resulting mixture was refluxed for 2 hr. After cooling to
room temperature, the mixture was refrigerated at &#x02212;20
&#x000b0;C overnight. The solid was filtered and washed with diethyl
ether to give the desired iodo salts as light yellow solids.</p><div id="ml083.fu9" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu10.jpg" alt="Image ml083fu10" /></div></div><p>Synthesis of ethyl
6-formyl-2-substituted-4H-thieno[3,2-b]pyrrole-5-carboxylates.</p><p>To a flask containing glacial acetic acid (5 ml) was added
1-((5-(ethoxycarbonyl)-2-substituted-4H-thieno[3,2-b]pyrrol-6-yl)methyl)-1-methylpiperidinium
iodides (2.30 g, 4.48 mmol) and the mixture was heated to 115
&#x000b0;C (oil bath), and hexamethylenetetramine (4.40 g, 31.4
mmol) was added as one portion and the temperature was kept at 115
&#x000b0;C for 20 min. After cooling to room temperature,
H<sub>2</sub>O (20 ml) was added and the resulting mixture was
extracted with EtOAc (3x25 ml) and the combined organic layers were
washed with saturated aqueous NaHCO<sub>3</sub> solution and brine.
After drying over Na<sub>2</sub>SO<sub>4</sub>, the organic solvent was
removed under reduced pressure and the residue was purified by column
chromatography (EtOAc/Hexane 1/6) to give the desired ethyl
6-formyl-2-substituted-4H-thieno[3,2-b]pyrrole-5-carboxylates
(302 mg, 40%) as white solids.</p><div id="ml083.fu10" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu11.jpg" alt="Image ml083fu11" /></div></div><p>Synthesis of ethyl
6-formyl-2,4-disubstituted-4H-thieno[3,2-b]pyrrole-5-carboxylates.</p><p>To a solution of ethyl
6-formyl-2-substituted-4H-thieno[3,2-b]pyrrole-5-carboxylates
(515 mg, 1.70 mmol) in DMF (5 ml) was added potassium carbonate (707 mg,
5.12 mmol) and iodomethane (0.27 ml, 3.40 mmol), and the resulting
mixture was stirred at room temperature for 2 hr. To the mixture was
added H<sub>2</sub>O (30 ml) and EtOAc (50 ml) and the organic layer was
separated and washed with brine, dried over
Na<sub>2</sub>SO<sub>4</sub>. After removing the organic solvent under
reduced pressure, the residue was purified by column chromatography
(EtOAc/Hexane 1/8) to give the desired <i>N</i>-methylated
ethyl
6-formyl-2,4-disubstituted-4H-thieno[3,2-b]pyrrole-5-carboxylates
(440 mg, 82%) as a white solid.</p><div id="ml083.fu11" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu12.jpg" alt="Image ml083fu12" /></div></div><p>Synthesis of substituted pyridazin-3(2H)-ones.</p><p>The
6-formyl-2,4-disubstituted-4H-thieno[3,2-b]pyrrole-5-carboxylates
(420 mg, 1.33 mmol) was dissolved in warm 2-ethoxyethanol (26 ml). To a
refluxed solution of hydrazine monohydrate (1 ml, 31.9 mmol) and
2-ethoxyethanol (5 ml) under nitrogen was added prepared
<i>N</i>-methylated ethyl
6-formyl-2,4-disubstituted-4H-thieno[3,2-b]pyrrole-5-carboxylates
solution dropwise over a 2 hr period, and the solution continued to
reflux for additional 1 hr. After cooling to room temperature, about
half of the 2-ethoxyethanol was removed under reduced pressure and the
remaining solution was refrigerated at &#x02212;20 &#x000b0;C
overnight. The precipitate was filtered and washed with 2-ethoxyethanol
to give desired substituted pyridazin-3(2H)-ones (354 mg,
94%) as white solids.</p><div id="ml083.fu12" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu13.jpg" alt="Image ml083fu13" /></div></div><p>Synthesis of substituted 2-benzylpyridazin-3(2H)-ones.</p><p>To a solution of substituted pyridazin-3(2H)-ones (354 mg, 1.25 mmol) in
DMF (5 ml) was added potassium carbonate (1.02 g, 7.35 mmol) and
2-fluorobenzyl bromide (0.94, 4.98), and the resulting mixture was
heated at 60 &#x000b0;C for 2 hr. After cooling to room temperature,
to the mixture H<sub>2</sub>O (20 ml) and EtOAc (50 ml) was added and
the organic layer was separated and washed with brine, dried over
Na<sub>2</sub>SO<sub>4</sub>. After removing the solvent under
reduced pressure, the residue was purified by column chromatography
(EtOAc/Hexane 1/4) to give substituted 2-benzylpyridazin-3(2H)-ones (371
mg, 76%) as white solids</p><div id="ml083.fu13" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu14.jpg" alt="Image ml083fu14" /></div></div><p><b>2,4-dimethyl-4H-thieno[3,2-b]pyrrole-2-(2-fluorobenzyl)pyridazin-3(2H)-one.</b>
<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 2.64 (d, 3H,
<i>J</i>=1.2 Hz), 4.27 (s, 3H), 5.53 (s, 2H),
6.92 (q, 1H, <i>J</i>=1.2 Hz),
7.02&#x02013;7.09 (m, 2H), 7.19&#x02013;7.26 (m, 2H), 8.20 (s,
1H). HRMS; Calculated for
C<sub>17</sub>H<sub>15</sub>FN<sub>3</sub>OS+
(M+H): 328.0920, found: 328.0925.</p></div><div id="ml083.s23"><h5>SAR of CID-654376 analogs</h5><p>The SAR of the substituted 2-benzylpyridazin-3(2H)-one chemotype was
explored on multiple fronts. The central 6:5:5 ring system was found to
be necessary as was the presence of the alkyl group of off the central
pyrole ring (methyl&#x0003e;ethyl&#x0003e;isoproply). Further, alkyl
groups at the 2 position of the thiophene ring were limited by size
(again, methyl&#x0003e;ethyl&#x0003e;isoproply). The lone phenyl ring was
explored with standard substitutions (F, Me, OMe, Cl, CF3) at all
positions (ortho, meta, para) and several di-substitutions were explored
(see table). Additionally, the 2-position of the thiophene ring was
explored in terms of heteroatomic substitutions (OMe, SMe, S(O)Me,
S(O<sub>2</sub>)Me, NO<sub>2</sub>) with varying results.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figml083tu7"><a href="/books/NBK47338/table/ml083.tu7/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figml083tu7" rid-ob="figobml083tu7"><img class="small-thumb" src="/books/NBK47338/table/ml083.tu7/?report=thumb" src-large="/books/NBK47338/table/ml083.tu7/?report=previmg" alt="SAR of CID-654376 analogs." /></a><div class="icnblk_cntnt"><h4 id="ml083.tu7"><a href="/books/NBK47338/table/ml083.tu7/?report=objectonly" target="object" rid-ob="figobml083tu7">Table</a></h4><p class="float-caption no_bottom_margin">SAR of CID-654376 analogs. </p></div></div><p>These compounds have been provided to the MLSMR: </p><p><b>MLS-00030964 (CID-650361)</b></p><p>
<i>Canonical SMILES</i>:
COC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)S(=O)(=O)C3=CC4=C(C=C3)OCCO4</p><p>
<i>InChI</i>: InChI
=1S/C19H22N2O7S2/c1-26-15-2-4-16(5-3-15)29(22,
23)20-8-10-21(11-9-20)30(24,25)17-6-7-18-19(14&#x02013;17)28-13-12-27-18/h2-7,
14H,8-13H2,1H3 </p><p><b>MLS-000076148 (CID-654376)</b></p><p>
<i>Canonical SMILES:</i>
CC1=CC2=C(S1)C3=C(N2C)C(=O)N(N=C3)CC4=CC=CC=C4F </p><p>
<i>InChI</i>:
InChI=1S/C17H14FN3OS/c1-10-7-14-16(23-10)12-8-19-21(17(22)15(12)20(14)2)
9-11-5-3-4-6-13(11)18/h3-8H,9H2,1-2H3 </p></div></div><div id="ml083.s25"><h4>Description of secondary assays used in probe characterization</h4><div id="ml083.s26"><h5>PK-LDH coupled</h5><p>A second assay was used to evaluate compounds. This assay couples the
formation of pyruvate from PK using lactate dehydrogenase (LDH) and
NADH. The depletion of NADH is followed in a fluorescent-based kinetic
assay that follows the formation of pyruvate to lactate, as catalyzed
LDH (described in ref [10]). This format can be
used to determine kinetic parameters and mechanism of action for
activators/inhibitors. This kinetic assay used 1 nM human PK-M2, and
initial rates are determined by measuring the fluorescence signal every
30 secs for 10 minutes. The same assay was used for isoform
selectivity.</p></div><div id="ml083.s27"><h5>Compound preparation</h5><p>Compound is prepared in DMSO at 10 mM stock concentration. Assays
described above have 0.6% DMSO final concentration in
buffer.</p></div></div></div></div><div id="ml083.s28"><h2 id="_ml083_s28_">Known probe properties</h2><p>Summary of probe properties (solubility, absorbance/fluorescence, reactivity,
toxicity, etc.) and recommendations for the scientific use of probe as research
tool:</p><div id="ml083.s29"><h3>1. Probe</h3><div id="ml083.s30"><h4>a. Chemical name</h4><p>
1-(2,3-dihydrobenzo[b][1,4]dioxin-6-ylsulfonyl)-4-(4-methoxyphenylsulfonyl)piperazine
[<a href="/pcsubstance/?term=ML083[synonym]" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=pubchem">ML083</a>]
</p></div><div id="ml083.s31"><h4>b. Probe chemical structure</h4><div id="ml083.fu14" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu16.jpg" alt="Image ml083fu16" /></div></div></div><div id="ml083.s32"><h4>c. Structural Verification Information of probe SID</h4><p><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i>6) &#x003b4;: 2.94 (s,
8H), 3.86 (s, 3H), 4.23&#x02013;4.45 (m, 4H), 7.01&#x02013;7.08 (m,
1H), 7.08&#x02013;7.19 (m, 4H), 7.57&#x02013;7.67 (m, 2H). HRMS;
Calculated for
C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O<sub>7</sub>S<sub>2</sub>
(M+): 454.0868, found: 454.0865.</p></div><div id="ml083.s33"><h4>d. PubChem CID (corresponding to the SID)</h4><p>CID-650361</p></div><div id="ml083.s34"><h4>e. Availability from a vendor</h4><p>Aliquots of MLS-00030964-01 (CID-650361) is available from the NCGC upon
request.</p></div><div id="ml083.s35"><h4>f. Mode of action for biological activity of probe</h4><p>The probe is a member of a series of highly specific allosteric activators
for the tumor-specific isoform of human pyruvate kinase (M2 isoform). The
activation occurs in a manner that is kinetically similar to the natural
activator (FBP) by decreasing the Km for PEP and reducing the cooperative
binding of PEP. Preliminary X-ray data obtained for co-crystals of
NCGC00030335 bound to human PK M2 (see PDB:3GQY) suggests this occurs by
binding at interface that spans the dimer-dimer interaction region of the
tetramer, which we infer stabilizes the high affinity R-state of the
tetramer.</p></div><div id="ml083.s36"><h4>g. Detailed synthetic pathway for making probe</h4><p>See schemes above.</p></div><div id="ml083.s37"><h4>h. Summary of probe properties</h4><p>Compound is soluble at 10 mM in DMSO. The compound is not fluorescent with
blue excitation wavelengths (~340 nm). Solubility in buffer has not been
determined.</p></div></div><div id="ml083.s38"><h3>2. Probe</h3><div id="ml083.s39"><h4>a. Chemical name</h4><p>
2,4-dimethyl-4H-thieno[3,2-b]pyrrole-2-(2-fluorobenzyl)pyridazin-3(2H)-one
[<a href="/pcsubstance/?term=ML082[synonym]" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=pubchem">ML082</a>]
</p></div><div id="ml083.s40"><h4>b. Probe chemical structure</h4><div id="ml083.fu15" class="figure"><div class="graphic"><img src="/books/NBK47338/bin/ml083fu17.jpg" alt="Image ml083fu17" /></div></div></div><div id="ml083.s41"><h4>c. Structural Verification Information of probe SID</h4><p><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x003b4; 2.64 (d, 3H,
<i>J</i>=1.2 Hz), 4.27 (s, 3H), 5.53 (s, 2H), 6.92
(q, 1H, <i>J</i>=1.2 Hz), 7.02&#x02013;7.09 (m,
2H), 7.19&#x02013;7.26 (m, 2H), 8.20 (s, 1H). HRMS; Calculated for
C<sub>17</sub>H<sub>15</sub>FN<sub>3</sub>OS+
(M+H): 328.0920, found: 328.0925.</p></div><div id="ml083.s42"><h4>d. PubChem CID (corresponding to the SID)</h4><p>CID-654376</p></div><div id="ml083.s43"><h4>e. Availability from a vendor</h4><p>Aliquots of MLS-000076148 (CID-654376) are available from the NCGC upon
request.</p></div><div id="ml083.s44"><h4>f. Mode of action for biological activity of probe</h4><p>The probe is a member of a series of highly specific allosteric activators
for the tumor-specific isoform of human pyruvate kinase (M2 isoform). The
activation occurs in a manner that is kinetically similar to the natural
activator (FBP) by decreasing the Km for PEP and reducing the cooperative
binding of PEP.</p></div><div id="ml083.s45"><h4>g. Detailed synthetic pathway for making probe</h4><p>See Scheme above.</p></div><div id="ml083.s46"><h4>h. Summary of probe properties</h4><p>Compound is soluble at 10 mM in DMSO. The compound is not fluorescent with
blue excitation wavelengths (~340 nm). Solubility in buffer has not been
determined.</p></div></div></div><div id="ml083.bib"><h2 id="_ml083_bib_">Bibliography</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="ml083.r1">Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric
regulation and catalysis. <span><span class="ref-journal">Biochemistry. </span>2005;<span class="ref-vol">44</span>:9417&ndash;29.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15996096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15996096</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="ml083.r2">Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for
cancer metabolism and tumour growth. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">452</span>:230&ndash;3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18337823" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18337823</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="ml083.r3">Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding
protein. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">452</span>:181&ndash;6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18337815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18337815</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="ml083.r4">Warburg O. On the origin of cancer cells. <span><span class="ref-journal">Science. </span>1956;<span class="ref-vol">123</span>:309&ndash;14.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13298683" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13298683</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="ml083.r5">Fan F, Wood KV. Bioluminescent assays for high-throughput
screening. <span><span class="ref-journal">Assay Drug Dev Technol. </span>2007;<span class="ref-vol">5</span>:127&ndash;36.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17355205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17355205</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="ml083.r6">Singh P, Harden BJ, Lillywhite BJ, Broad PM. Identification of kinase inhibitors by an ATP depletion
method. <span><span class="ref-journal">Assay Drug Dev Technol. </span>2004;<span class="ref-vol">2</span>:161&ndash;9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15165512" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15165512</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="ml083.r7">Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W, Austin CP. Quantitative high-throughput screening: A titration-based
approach that efficiently identifies biological activities in large
chemical libraries. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2006;<span class="ref-vol">103</span>:11473&ndash;8.</span> [<a href="/pmc/articles/PMC1518803/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1518803</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16864780" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16864780</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="ml083.r8">Auld DS, Zhang YQ, Southall NT, Rai G, Landsman M, Maclure J, Langevin D, Thomas CJ, Austin CP, Inglese J. A Basis for Reduced Chemical Library Inhibition of Firefly
Luciferase Obtained from Directed Evolution. <span><span class="ref-journal">J Med Chem. </span>2009;<span class="ref-vol">52</span>:1450&ndash;1458.</span> [<a href="/pmc/articles/PMC3430137/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3430137</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19215089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19215089</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="ml083.r9">Yasgar A, Shinn P, Jadhav A, Auld DS, Michael S, Zheng W, Austin CP, Inglese J, Simeonov A. Compound Management for Quantitative High-Throughput
Screening. <span><span class="ref-journal">J Assoc Lab Automation. </span>2008;<span class="ref-vol">13</span>:79&ndash;89.</span> [<a href="/pmc/articles/PMC2390859/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2390859</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18496600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18496600</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="ml083.r10">Hannaert V, Yernaux C, Rigden DJ, Fothergill-Gilmore LA, Opperdoes FR, Michels PA. The putative effector-binding site of Leishmania mexicana
pyruvate kinase studied by site-directed mutagenesis. <span><span class="ref-journal">FEBS Lett. </span>2002;<span class="ref-vol">514</span>:255&ndash;9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11943161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11943161</span></a>]</div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK47338_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Douglas Auld</span>, <span itemprop="author">Min Shen</span>, <span itemprop="author">Amanda P Skoumbourdis</span>, <span itemprop="author">Jian-kang Jiang</span>, <span itemprop="author">Matthew Boxer</span>, <span itemprop="author">Noel Southall</span>, <span itemprop="author">James Inglese</span>, and <span itemprop="author">Craig Thomas</span>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> NIH Chemical Genomics Center</div><h3>Publication History</h3><p class="small">Received: <span itemprop="datePublished">April 16, 2009</span>; Last Update: <span itemprop="dateModified">August 6, 2010</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p>National Center for Biotechnology Information (US), Bethesda (MD)</p><h3>NLM Citation</h3><p>Auld D, Shen M, Skoumbourdis AP, et al. Identification of activators for the M2 isoform of human pyruvate kinase. 2009 Apr 16 [Updated 2010 Aug 6]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/mlprobe/ml084/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/mlprobe/ml081/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobml083tu1"><div id="ml083.tu1" class="table"><h3><span class="title">Probe 1 Structure &#x00026; Characteristics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47338/table/ml083.tu1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml083.tu1_lrgtbl__"><table class="no_top_margin"><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PubChem CID</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CID-650361</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SID</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/847943" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-847943</a></td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Internal ID</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">NCGC-00030335</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Molecular Weight</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">454.52</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Molecular Formula</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O<sub>7</sub>S<sub>2</sub></td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XLogP</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">H-Bond Donor</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">H-Bond Acceptor</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rotatable Bond Count</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exact Mass</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">454.086842</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Topological Polar Surface Area</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">103</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Heavy Atom Count</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">30</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml083fu1"><div id="ml083.fu1" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu1.jpg" alt="Image ml083fu1" /></div></div></article><article data-type="table-wrap" id="figobml083tu2"><div id="ml083.tu2" class="table"><h3><span class="title">PubChem Primary Bioassay Identifier (AID): 1631</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47338/table/ml083.tu2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml083.tu2_lrgtbl__"><table class="no_top_margin"><thead><tr><th id="hd_h_ml083.tu2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CID/ML</th><th id="hd_h_ml083.tu2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Target Name</th><th id="hd_h_ml083.tu2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IC50/EC 50 (nM) [SID,
AID]</th><th id="hd_h_ml083.tu2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Anti-target Name(s)</th><th id="hd_h_ml083.tu2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IC50/EC50 (&#x003bc;M) [SID,
AID]</th><th id="hd_h_ml083.tu2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Selectivity</th><th id="hd_h_ml083.tu2_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Secondary Assay(s) Name: IC50/EC50 (nM)
[SID, AID]</th></tr></thead><tbody><tr><td headers="hd_h_ml083.tu2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">650361/<a href="/pcsubstance/?term=ML083[synonym]" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=pubchem">ML083</a></td><td headers="hd_h_ml083.tu2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPK-M2</td><td headers="hd_h_ml083.tu2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.6 &#x000b1; 0.3 [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/847943" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-847943</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1540" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1540</a>]</td><td headers="hd_h_ml083.tu2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPK-R</td><td headers="hd_h_ml083.tu2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30%@ 57 &#x003bc;M
[<a href="https://pubchem.ncbi.nlm.nih.gov/substance/847943" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-847943</a>, <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1543" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1543</a>]</td><td headers="hd_h_ml083.tu2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02265; 30-fold</td><td headers="hd_h_ml083.tu2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PK-LDH, [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/847943" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-847943</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1543" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1543</a>]</td></tr><tr><td headers="hd_h_ml083.tu2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPK-L</td><td headers="hd_h_ml083.tu2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inactive[<a href="https://pubchem.ncbi.nlm.nih.gov/substance/847943" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-847943</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1541" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1541</a>]</td><td headers="hd_h_ml083.tu2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02265; 100-fold</td><td headers="hd_h_ml083.tu2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PK-LDH, [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/847943" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-847943</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1541" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1541</a>]</td></tr><tr><td headers="hd_h_ml083.tu2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPK-M1</td><td headers="hd_h_ml083.tu2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inactive[<a href="https://pubchem.ncbi.nlm.nih.gov/substance/847943" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-847943</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1542" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1542</a>]</td><td headers="hd_h_ml083.tu2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02265; 100-fold</td><td headers="hd_h_ml083.tu2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PK-LDH, [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/847943" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-847943</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1542" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1542</a>]</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobml083tu3"><div id="ml083.tu3" class="table"><h3><span class="title">Probe 2 Structure &#x00026; Characteristics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47338/table/ml083.tu3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml083.tu3_lrgtbl__"><table class="no_top_margin"><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PubChem CID</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CID-654376</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SID</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/851783" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-851783</a></td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Internal ID</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">NCGC-00031955</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Molecular Weight</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">327.38</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Molecular Formula</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">C17H14FN3OS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XLogP</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">H-Bond Donor</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">H-Bond Acceptor</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rotatable Bond Count</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exact Mass</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">327.08</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Topological Polar Surface Area</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">37.6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Heavy Atom Count</td><td rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">23</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml083fu2"><div id="ml083.fu2" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu2.jpg" alt="Image ml083fu2" /></div></div></article><article data-type="table-wrap" id="figobml083tu4"><div id="ml083.tu4" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47338/table/ml083.tu4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml083.tu4_lrgtbl__"><table><thead><tr><th id="hd_h_ml083.tu4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CID/ML</th><th id="hd_h_ml083.tu4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Target Name</th><th id="hd_h_ml083.tu4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IC50/EC 50 (nM) [SID,
AID]</th><th id="hd_h_ml083.tu4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Anti-target Name(s)</th><th id="hd_h_ml083.tu4_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IC50/EC50 (&#x003bc;M) [SID,
AID]</th><th id="hd_h_ml083.tu4_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Selectivity</th><th id="hd_h_ml083.tu4_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Secondary Assay(s) Name: IC50/EC50 (nM)
[SID, AID]</th></tr></thead><tbody><tr><td headers="hd_h_ml083.tu4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CID-654376/<a href="/pcsubstance/?term=ML082[synonym]" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=pubchem">ML082</a></td><td headers="hd_h_ml083.tu4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPK-M2</td><td headers="hd_h_ml083.tu4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.2 &#x000b1; 0.1 [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/851783" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-851783</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1540" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1540</a>]</td><td headers="hd_h_ml083.tu4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPK-L</td><td headers="hd_h_ml083.tu4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/851783" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-851783</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1541" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1541</a>]</td><td headers="hd_h_ml083.tu4_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x0003e;10 fold</td><td headers="hd_h_ml083.tu4_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PK-LDH, [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/851783" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-851783</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1541" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1541</a>]</td></tr><tr><td headers="hd_h_ml083.tu4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPK-R</td><td headers="hd_h_ml083.tu4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/851783" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-851783</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1543" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1543</a>]</td><td headers="hd_h_ml083.tu4_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x0003e;10 fold</td><td headers="hd_h_ml083.tu4_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PK-LDH, [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/851783" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-851783</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1543" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1543</a>]</td></tr><tr><td headers="hd_h_ml083.tu4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ml083.tu4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPK-M1</td><td headers="hd_h_ml083.tu4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inactive [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/851783" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-851783</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1542" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1542</a>]</td><td headers="hd_h_ml083.tu4_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x0003e;100 fold</td><td headers="hd_h_ml083.tu4_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PK-LDH, [<a href="https://pubchem.ncbi.nlm.nih.gov/substance/851783" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">SID-851783</a>,
<a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1542" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-1542</a>]</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml083fu3"><div id="ml083.fu3" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu3.jpg" alt="A) Shown is normal respiration occurring in non-cancerous cell-types" /></div><div class="caption"><p><b>A)</b> Shown is normal respiration occurring in non-cancerous
cell-types. PK-M1 is constitutively active and acts primarily to drive
ATP formation. <b>B)</b> Shown is altered metabolism that occurs
in cancer cells. In this case, the activity of the PK-M2 isoform is
activated by phosphorylated sugars (e.g. FBP) and inhibited by
tyrosine-phosphorylated proteins derived from growth factor signaling.
The decrease in activity of PK-M2 in response to growth signals is
predicted to build-up intermediates of glycolysis and feed proliferation
of the cancer cells.</p></div></div></article><article data-type="table-wrap" id="figobml083tu5"><div id="ml083.tu5" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47338/table/ml083.tu5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml083.tu5_lrgtbl__"><table><thead><tr><th id="hd_h_ml083.tu5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">AID</th><th id="hd_h_ml083.tu5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Target</th><th id="hd_h_ml083.tu5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Concentration</th><th id="hd_h_ml083.tu5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Bioassay type</th></tr></thead><tbody><tr><td headers="hd_h_ml083.tu5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1631" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">1631</a></td><td headers="hd_h_ml083.tu5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPKM2 Activator</td><td headers="hd_h_ml083.tu5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 &#x003bc;M to 0.4 nM</td><td headers="hd_h_ml083.tu5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Primary qHTS</td></tr><tr><td headers="hd_h_ml083.tu5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1634" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">1634</a></td><td headers="hd_h_ml083.tu5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPKM2 Inhibitor</td><td headers="hd_h_ml083.tu5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 &#x003bc;M to 0.4 nM</td><td headers="hd_h_ml083.tu5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Primary qHTS</td></tr><tr><td headers="hd_h_ml083.tu5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1540" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">1540</a></td><td headers="hd_h_ml083.tu5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPKM2</td><td headers="hd_h_ml083.tu5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 &#x003bc;M to 0.4 nM</td><td headers="hd_h_ml083.tu5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Confirmatory</td></tr><tr><td headers="hd_h_ml083.tu5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1541" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">1541</a></td><td headers="hd_h_ml083.tu5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPKL</td><td headers="hd_h_ml083.tu5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 &#x003bc;M to 0.4 nM</td><td headers="hd_h_ml083.tu5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selectivity</td></tr><tr><td headers="hd_h_ml083.tu5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1542" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">1542</a></td><td headers="hd_h_ml083.tu5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPKM1</td><td headers="hd_h_ml083.tu5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 &#x003bc;M to 0.4 nM</td><td headers="hd_h_ml083.tu5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selectivity</td></tr><tr><td headers="hd_h_ml083.tu5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/1543" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">1543</a></td><td headers="hd_h_ml083.tu5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hPKR</td><td headers="hd_h_ml083.tu5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 &#x003bc;M to 0.4 nM</td><td headers="hd_h_ml083.tu5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selectivity</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml083f1"><div id="ml083.f1" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083f1.jpg" alt="Figure 2. Pyruvate kinase-luciferase coupled assay." /></div><h3><span class="label">Figure 2</span><span class="title">Pyruvate kinase-luciferase coupled assay</span></h3></div></article><article data-type="table-wrap" id="figobml083t1"><div id="ml083.t1" class="table"><h3><span class="label">Table 1</span><span class="title">Final 1536-well assay protocol</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47338/table/ml083.t1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml083.t1_lrgtbl__"><table class="no_top_margin"><thead><tr><th id="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Step</th><th id="hd_h_ml083.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Parameter</th><th id="hd_h_ml083.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Value</th><th id="hd_h_ml083.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Description</th></tr></thead><tbody><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ml083.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reagent</td><td headers="hd_h_ml083.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 &#x003bc;L</td><td headers="hd_h_ml083.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PEP/hPK-M2 buffer (0.5 mM and 0.1
nM final, respectively)</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ml083.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Controls</td><td headers="hd_h_ml083.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 nl</td><td headers="hd_h_ml083.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Activator control
(NCGC00031955)</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ml083.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Library compounds</td><td headers="hd_h_ml083.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 nl</td><td headers="hd_h_ml083.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 &#x003bc;M to 0.4 nM
dilution series</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ml083.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reagent</td><td headers="hd_h_ml083.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 &#x003bc;L</td><td headers="hd_h_ml083.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ADP buffer (0.1 mM final)</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5</td><td headers="hd_h_ml083.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incubation time</td><td headers="hd_h_ml083.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 hr</td><td headers="hd_h_ml083.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Room temperature</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_ml083.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reagent</td><td headers="hd_h_ml083.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 &#x003bc;L</td><td headers="hd_h_ml083.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kinase-Glo</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7</td><td headers="hd_h_ml083.t1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assay readout</td><td headers="hd_h_ml083.t1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">luminescence</td><td headers="hd_h_ml083.t1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ViewLux</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1 hd_h_ml083.t1_1_1_1_2 hd_h_ml083.t1_1_1_1_3 hd_h_ml083.t1_1_1_1_4" colspan="4" rowspan="1" style="vertical-align:top;"><b>Step Notes</b></td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">1</td><td headers="hd_h_ml083.t1_1_1_1_2 hd_h_ml083.t1_1_1_1_3 hd_h_ml083.t1_1_1_1_4" colspan="3" rowspan="1" style="vertical-align:top;">Black walled clear bottom Greiner white solid plates; 4 tips
dispense to all wells except column 3 of buffer 0.133 nM hPK-M2,
0.67 mM PEP, 50 mM Imidazole pH 7.2, 50 mM KCl, 7 mM MgCl2,
0.01% Tween, 0.05% BSA. Column 3, 1 tip of
same buffer without hPK-M2.</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">2</td><td headers="hd_h_ml083.t1_1_1_1_2 hd_h_ml083.t1_1_1_1_3 hd_h_ml083.t1_1_1_1_4" colspan="3" rowspan="1" style="vertical-align:top;">Column 1, NCGC00031955 Activator titration 57 &#x003bc;M start,
16 points in duplicate 1:2 dilutions; Column 2 neutral, DMSO only;
Column 3 no enzyme; Column 4, top 16 rows are NCGC0031955 at 57
&#x003bc;M, bottom 16 rows are DMSO only.</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">3</td><td headers="hd_h_ml083.t1_1_1_1_2 hd_h_ml083.t1_1_1_1_3 hd_h_ml083.t1_1_1_1_4" colspan="3" rowspan="1" style="vertical-align:top;">Pintool transfer (tip wash sequence; DMSO, iPA, MeOH, 3-s vacuum
dry)</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4</td><td headers="hd_h_ml083.t1_1_1_1_2 hd_h_ml083.t1_1_1_1_3 hd_h_ml083.t1_1_1_1_4" colspan="3" rowspan="1" style="vertical-align:top;">ADP in same 4 tips dispense to all wells of buffer containing 0.4
mM ADP (final assay 0.1 mM), 50 mM Imidazole pH 7.2, 50 mM KCl, 7 mM
MgCl2, 0.01% Tween, 0.05% BSA.</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">5</td><td headers="hd_h_ml083.t1_1_1_1_2 hd_h_ml083.t1_1_1_1_3 hd_h_ml083.t1_1_1_1_4" colspan="3" rowspan="1" style="vertical-align:top;">Plates covered with stainless steel rubber gasket-lined lids
containing pin holes for gas exchange</td></tr><tr><td headers="hd_h_ml083.t1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">6</td><td headers="hd_h_ml083.t1_1_1_1_2 hd_h_ml083.t1_1_1_1_3 hd_h_ml083.t1_1_1_1_4" colspan="3" rowspan="1" style="vertical-align:top;">Kinase-Glo detection. Luciferase-based detection of ATP product</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml083f2"><div id="ml083.f2" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083f2.jpg" alt="Figure 2. qHTS Performance Summary." /></div><h3><span class="label">Figure 2</span><span class="title">qHTS Performance Summary</span></h3></div></article><article data-type="fig" id="figobml083f3"><div id="ml083.f3" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083f3.jpg" alt="Scheme 1. Example qHTS data and classification scheme for assignment of resulting curve-fit data into classes." /></div><h3><span class="label">Scheme 1</span><span class="title">Example qHTS data and classification scheme for assignment of
resulting curve-fit data into classes</span></h3><div class="caption"><p><b>Top</b>, qHTS curve-fit data from <a href="https://pubchem.ncbi.nlm.nih.gov/bioassay/361" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">AID-361</a> binned into
curve classifications 1&#x02013;4 based classification
criteria. <b>Below</b>, Examples of curves fitting the
following classification criteria: Class 1 curves display two
asymptotes, an inflection point, and r2 &#x02265; 0.9;
subclasses 1a (blue) vs. 1b (orange) are differentiated by full
(&#x0003e;80%) vs. partial (&#x02264;
80%) response. Class 2 curves display a single
left-hand asymptote and inflection point; subclasses 2a (blue)
and 2b (orange) are differentiated by a max response and r2,
&#x0003e;80% and &#x0003e;0.9 or
&#x0003c;80% and &#x0003c;0.9, respectively. Class 3
curves have a single left-hand asymptote, no inflection point,
and a response &#x0003e;3SD the mean activity of the sample
field. Class 4 defines those samples showing no activity across
the concentration range. Specifically, for the identification of
the Probe series 1, the filtering shown in <a class="figpopup" href="/books/NBK47338/figure/ml083.f4/?report=objectonly" target="object" rid-figpopup="figml083f4" rid-ob="figobml083f4">Figure 3</a> below was used.</p></div></div></article><article data-type="fig" id="figobml083f4"><div id="ml083.f4" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083f4.jpg" alt="Figure 3. Summary of activity from the qHTS." /></div><h3><span class="label">Figure 3</span><span class="title">Summary of activity from the qHTS</span></h3><div class="caption"><p>The table summarizes the number actives associated with CRC
classes described in <a class="figpopup" href="/books/NBK47338/figure/ml083.f1/?report=objectonly" target="object" rid-figpopup="figml083f1" rid-ob="figobml083f1">Scheme
1</a>(highlighted in red are the percentages for the high
quality activating CRCs. The flow chart below summarizes the how
this information was used to subsequently used to define
SAR.</p></div></div></article><article data-type="fig" id="figobml083fu4"><div id="ml083.fu4" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu4.jpg" alt="Mode of action." /></div><h3><span class="title">Mode of action</span></h3><div class="caption"><p>Both CID-650361 (<b>A</b>) and CID-654376 (<b>B</b>) affect
the cooperativity of PEP binding with little affect on ADP binding in a
manner similar to FBP but with lower efficacy. Kinetics of substrate
binding in the presence (open circles) or absence (filled squares) of
activator (10 &#x003bc;M was used). Vo, initial rate in pmol/min as
determined in the PK-LDH coupled assay</p></div></div></article><article data-type="fig" id="figobml083f5"><div id="ml083.f5" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083f5.jpg" alt="Scheme 1" /></div><h3><span class="label">Scheme 1</span></h3></div></article><article data-type="fig" id="figobml083f6"><div id="ml083.f6" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083f6.jpg" alt="Scheme 2" /></div><h3><span class="label">Scheme 2</span></h3></div></article><article data-type="fig" id="figobml083f7"><div id="ml083.f7" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083f7.jpg" alt="Scheme 3" /></div><h3><span class="label">Scheme 3</span></h3></div></article><article data-type="fig" id="figobml083f8"><div id="ml083.f8" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083f8.jpg" alt="Scheme 4" /></div><h3><span class="label">Scheme 4</span></h3></div></article><article data-type="table-wrap" id="figobml083tu6"><div id="ml083.tu6" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47338/table/ml083.tu6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml083.tu6_lrgtbl__"><table><thead><tr><th id="hd_h_ml083.tu6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th id="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>1</sub></th><th id="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>2</sub></th><th id="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>3</sub></th><th id="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>4</sub></th><th id="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>5</sub></th><th id="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">
<i>IC</i>
<i>
<sub>50</sub>
</i>
<i>(&#x003bc;M)</i>
</th><th id="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">
<i>Max Responce</i>
</th></tr></thead><tbody><tr><td headers="hd_h_ml083.tu6_1_1_1_1" rowspan="17" colspan="1" style="text-align:left;vertical-align:top;">
<div class="graphic"><img src="/books/NBK47338/bin/ml083fu5.jpg" alt="Image ml083fu5.jpg" /></div>
</td><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.398</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">310</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">OMe</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.562</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">195</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.708</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">162</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">OCF3</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.00</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">21</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.708</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">369</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Br</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.47</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">310</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">COOH</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15.8</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">164</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CH<sub>2</sub>COOH</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">17.8</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">276</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><i>n</i>Pr</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">31.6</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">234</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">COOMe</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.224</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">306</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">COOH</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.355</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12.5</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">OMe</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.447</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">103</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">OH</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.562</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">227</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">OMe</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.00</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">232</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.21</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">199</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CF<sub>3</sub></td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.26</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">193</td></tr><tr><td headers="hd_h_ml083.tu6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu6_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu6_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.58</td><td headers="hd_h_ml083.tu6_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">229</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml083f9"><div id="ml083.f9" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083f9.jpg" alt="Scheme 5" /></div><h3><span class="label">Scheme 5</span></h3></div></article><article data-type="fig" id="figobml083fu5"><div id="ml083.fu5" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu6.jpg" alt="Image ml083fu6" /></div></div></article><article data-type="fig" id="figobml083fu6"><div id="ml083.fu6" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu7.jpg" alt="Image ml083fu7" /></div></div></article><article data-type="fig" id="figobml083fu7"><div id="ml083.fu7" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu8.jpg" alt="Image ml083fu8" /></div></div></article><article data-type="fig" id="figobml083fu8"><div id="ml083.fu8" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu9.jpg" alt="Image ml083fu9" /></div></div></article><article data-type="fig" id="figobml083fu9"><div id="ml083.fu9" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu10.jpg" alt="Image ml083fu10" /></div></div></article><article data-type="fig" id="figobml083fu10"><div id="ml083.fu10" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu11.jpg" alt="Image ml083fu11" /></div></div></article><article data-type="fig" id="figobml083fu11"><div id="ml083.fu11" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu12.jpg" alt="Image ml083fu12" /></div></div></article><article data-type="fig" id="figobml083fu12"><div id="ml083.fu12" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu13.jpg" alt="Image ml083fu13" /></div></div></article><article data-type="fig" id="figobml083fu13"><div id="ml083.fu13" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu14.jpg" alt="Image ml083fu14" /></div></div></article><article data-type="table-wrap" id="figobml083tu7"><div id="ml083.tu7" class="table"><h3><span class="title">SAR of CID-654376 analogs</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK47338/table/ml083.tu7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ml083.tu7_lrgtbl__"><table class="no_top_margin"><thead><tr><th id="hd_h_ml083.tu7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th id="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>1</sub></th><th id="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>2</sub></th><th id="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>3</sub></th><th id="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>4</sub></th><th id="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">R<sub>5</sub></th><th id="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">
<i>IC</i>
<i>
<sub>50</sub>
</i>
<i>( &#x003bc;M)</i>
</th><th id="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">
<i>Max Responce</i>
</th></tr></thead><tbody><tr><td headers="hd_h_ml083.tu7_1_1_1_1" rowspan="45" colspan="1" style="text-align:left;vertical-align:top;">
<div class="graphic"><img src="/books/NBK47338/bin/ml083fu15.jpg" alt="Image ml083fu15.jpg" /></div>
</td><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.200</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">354</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.251</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">330</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.282</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">331</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">OMe</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.282</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">353</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.316</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">302</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.316</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">389</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CF<sub>3</sub></td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.316</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">316</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.355</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">365</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.398</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">322</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.398</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">389</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.447</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">313</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">OMe</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.501</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">409</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.501</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">322</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.562</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">293</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.562</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">335</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.631</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">324</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.631</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">382</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Br</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.631</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">384</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.631</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">326</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Br</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.708</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">318</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.708</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">308</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.708</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">309</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.708</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">332</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.708</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">323</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.794</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">355</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.794</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">348</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.794</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">303</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.794</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">285</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.891</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">309</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.891</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">351</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.891</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">62</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.00</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">380</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.00</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">321</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.12</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">323</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.12</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">343</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">OMe</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.41</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">297</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.41</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">307</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.59</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.59</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">272</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Br</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.59</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">250</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CF<sub>3</sub></td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.78</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">292</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.78</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">335</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Me</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.00</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">381</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Cl</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.00</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">347</td></tr><tr><td headers="hd_h_ml083.tu7_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">F</td><td headers="hd_h_ml083.tu7_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">H</td><td headers="hd_h_ml083.tu7_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.00</td><td headers="hd_h_ml083.tu7_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">266</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobml083fu14"><div id="ml083.fu14" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu16.jpg" alt="Image ml083fu16" /></div></div></article><article data-type="fig" id="figobml083fu15"><div id="ml083.fu15" class="figure"><div class="graphic"><img data-src="/books/NBK47338/bin/ml083fu17.jpg" alt="Image ml083fu17" /></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
<!-- Book content -->
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
</html>